赵法宝，副研究员，博士，药物化学专业。主持国自然青年基金项目及省部级课题6项，作为项目骨干参与科技部重点研发计划、国自然面上项目以及山东省重点研发计划等科研项目。研究方向聚焦于计算机/人工智能辅助药物设计以及靶向NMDA受体的抗抑郁创新药物研究工作。在J. Am. Chem. Soc.，J. Med. Chem.（四篇），J. Chem. Inf. Model等期刊其中以（共同）第一作者身份发表论文10篇，参与发表SCI论文60余篇。

学习与工作经历： 

2025.09- 至今 山东大学，副研究员

2021.05-2025.05，山东大学，药物化学专业，特别资助类博士后，导师：刘新泳 教授

2016.10 - 2021.5，丹麦University of Copenhagen，药物化学系，博士，导师：Rasmus P. Clausen

2013.09 - 2016.06，山东大学，药物化学专业，硕士，导师：刘新泳 教授

2009.09 - 2013.06，西安交通大学，制药工程专业，本科

研究方向： 

计算机辅助药物设计

AI蛋白质设计

NMDA受体亚型选择性调控剂的开发

学术/社会兼职：

Scientific Reports 青年编委

获奖荣誉：

本科生课程：

药剂学实验

研究生课程：

1.山东省重点研发计划（竞争性创新平台）项目，2025.07-2028.07，85万，主持。

2.国家自然科学基金青年科学基金项目，2023.01-2025.12，30万，主持。

3.博士后国际交流计划引进项目，2021.11，60万，主持。

4.中国博士后科学基金面上资助，8万，2022.06，主持。

5.山东省自然科学基金青年基金项目，2022.01-2025.12，15万，主持。

6.国家留学基金委公派留学项目，2016.10-2020.10，主持。

1.Fabao Zhao, Unai Atxabal, Sofia Mariottini, Feng Yi, James S. Lotti, Michael S. Layeux, Chandler Currier, Matthew P. Maderia, Lauren E. Conelison, Carly M. Anderson, Eric P. Schultz, Zhucheng Zhang, Liyang Jiang, Zhen Gao, Na Liu, Erica L. Woodahl, Lennart Bunch, Kasper B. Hansen,* Rasmus P. Clausen.* Design of (R)-3-(5-Thienyl)carboxamido-2-aminopropanoic Acid Derivatives as Novel NMDA Receptor Glycine Site Agonists: Variation in Molecular Geometry to Improve Potency and Augment GluN2 Subunit-Specific Activity. Journal of Medicinal Chemistry, 2025, 68(3): 3572-3590.

2. Ting Dong,#*Fabao Zhao,# Mengmeng Wang,# Kaige Lyu,# Jiayu Zhu, Wenru Zhang, Wenzhe Li, Yixuan An, Na Liu, Akhand Pratap Singh, Yue Yang, Dongwei Kang,* Xiaohui Liu.* G3BP1/2-targeting PROTAC disrupts stress granules dependent ATF4 migracytosis as cancer therapy. Journal of the American Chemical Society, 2025, 147(1): 446-461.

3.Fabao Zhao,# Liyang Jiang,# Jieying Xie, Na Liu, Zhen Gao, Yue Yang, Yu Wang, Boshi Huang, Dongwei Kang, Peng Zhan,* Feng Yi,* Xinyong Liu.* Discovery of Brain-Penetrative Negative Allosteric Modulators of NMDA Receptors using FEP-guided structure optimization and membrane permeability prediction. Journal of Chemical Information and Modeling, 2025, 65(2): 857-872.

4. Xue Wang,# Xueyang Jin,#Fabao Zhao,# Zejun Xu, Wenzhuo Tan, Jiaozhen Zhang, Yuliang Xu, Xiaoyi Luan, Min Fang, Zhiyu Xie, Wenqiang Chang,* Hongxiang Lou.* Structure-Based Optimization of Novel Sterol 24-C-Methyltransferase Inhibitors for the Treatment of Candida albicans Infections. Journal of Medicinal Chemistry, 2024, 67(11): 9318-9341.

5.Fabao Zhao,# Heng Zhang,# Minghui Xie, Bairu Meng, Na Liu, Caiyun Dun, Yanyang Qin, Shenghua Gao, Erik De Clercq, Christophe Pannecouque, Ya-Jie Tang, Peng Zhan,* Xinyong Liu,* Dongwei Kang.* Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’Binding Pocket. Journal of Medicinal Chemistry, 2023, 66(3): 2102-2115.

6.Fabao Zhao, Unai Atxabal, Sofia Mariottini, Feng Yi, James S. Lotti, Nirvan Rouzbeh, Na Liu, Lennart Bunch, Kasper B. Hansen,* Rasmus P. Clausen.* Derivatives of (R)-3-(5-Furanyl)carboxamido-2-aminopro panoic Acid as Potent NMDA Receptor Glycine Site Agonists with GluN2 Subunit-Specific Activity. Journal of Medicinal Chemistry. 2022, 65(1): 734-746.

7.Fabao Zhao,* Georgios Mazis, Feng Yi, James S Lotti, Michael S Layeux, Eric P Schultz, Lennart Bunch, Kasper B Hansen,* Rasmus P Clausen.* Discovery of (R)-2-amino-3-triazolpropanoic acid derivatives as NMDA receptor glycine site agonists with GluN2 subunit-specific activity. Frontiers in Chemistry, 2022, 10: 1008233.

8.Fabao Zhao, Nirvan Rouzbeh, Kasper B. Hansen, Rasmus P. Clausen.* Improved synthetic route for the GluN2-specific NMDA receptor glycine site agonist AICP. Tetrahedron Letters, 2020, 61(12): 151653.

9.Fabao Zhao, Na Liu, Peng Zhan, Xinyong Liu.* Repurposing of Hdac Inhibitors Toward Anti-Hepatitis C Virus Drug Discovery: Teaching an Old Dog New Tricks. Future Medicinal Chemistry, 2015, 7(11): 1367-1371.

10.Fabao Zhao, Na Liu, Peng Zhan,* Xuemei Jiang,* Xinyong Liu.* Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold. European Journal of Medicinal Chemistry, 2015, 94: 218-228.